View Older Stories View More Recent Stories

Jan 18, 2020 09:00AM Significant Study on Veterinary Wellbeing Reveals Importance of Continued Focus on Personal and Professional Health and Wellbeing Among Veterinarians
Jan 16, 2020 08:34AM Merck (MRK) Completes Acquisition of ArQule (ARQL)
Jan 16, 2020 08:34AM Merck Completes Acquisition of ArQule
Jan 8, 2020 04:33PM Merck (MRK) Announces FDA Approved its KEYTRUDA for Patients With BCG-Unresponsive, High-Risk, NMIBC With CIS With or Without Papillary Tumors
Jan 8, 2020 04:31PM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer With Carcinoma In Situ With or Without Papillary Tumors Who Are Inel
Jan 6, 2020 04:06PM Merck's (MRK) KEYTRUDA in Combination with Chemotherapy Significantly Improved PFS Compared to Chemotherapy Alone as First-Line Treatment for ES-SCLC
Jan 6, 2020 04:05PM Merck’s KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Significantly Improved Progression-Free Survival Compared to Chemotherapy Alone as First-Line Treatment for Extensive Stage Small
Jan 6, 2020 07:00AM BAVENCIO Significantly Improved Overall Survival in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Jan 6, 2020 06:31AM Merck (MRK) Announces Strategic Oncology Collaboration with Taiho and Astex
Jan 6, 2020 06:30AM Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
Jan 3, 2020 06:45AM Merck to Hold Fourth-Quarter and Full-Year 2019 Sales and Earnings Conference Call on February 5
Jan 2, 2020 06:45AM Merck to Present at the 38th Annual J.P. Morgan Healthcare Conference
Dec 30, 2019 06:55AM LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer
Dec 20, 2019 07:16AM Merck (MRK) Confirms FDA Approval for ERVEBO (Ebola Zaire Vaccine, Live)
Dec 20, 2019 07:15AM Merck Announces FDA Approval for ERVEBO® (Ebola Zaire Vaccine, Live)
Dec 20, 2019 06:46AM Merck's (MRK) KEYTRUDA Approved in Japan for Three New First-Line Indications Across Advanced RCC and Recurrent or Distant Metastatic Head and Neck Cancer
Dec 20, 2019 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer
Dec 19, 2019 08:00AM MilliporeSigma Licenses Foundational CRISPR Integration Technology to Promega
Dec 17, 2019 05:16PM Merck (MRK) Announces FDA ODAC Recommends KEYTRUDA for Treatment of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer
Dec 17, 2019 05:15PM FDA Oncologic Drugs Advisory Committee (ODAC) Recommends KEYTRUDA® (pembrolizumab) for the Treatment of Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)
Dec 17, 2019 05:00PM Merck Animal Health Completes Acquisition of Vaki to Further Broaden Its Leadership Position in Aquaculture to Advance Fish Health and Welfare
Dec 17, 2019 02:10PM AstraZeneca (AZN), Merck (MRK) Announce LYNPARZA Recommended by FDA Advisory Committee for First-Line Maintenance Therapy in Germline BRCA-Mutated Metastatic Pancreatic Cancer
Dec 17, 2019 02:09PM LYNPARZA® (olaparib) Recommended by FDA Advisory Committee for First-Line Maintenance Therapy in Germline BRCA-Mutated Metastatic Pancreatic Cancer That Has Not Progressed on Platinum-Based Chemother
Dec 17, 2019 06:46AM Merck (MRK) Begins Tender Offer to Acquire ArQule (ARQL)
Dec 17, 2019 06:45AM Merck Begins Tender Offer to Acquire ArQule
Dec 12, 2019 06:47AM Merck (MRK) Reports Data from Exploratory Analysis Shows KEYTRUDA (pembrolizumab) Improved OS as Monotherapy for First-Line Treatment of Metastatic NSCLC
Dec 12, 2019 06:45AM Data from Exploratory Analysis Show Merck’s KEYTRUDA® (pembrolizumab) Improved Overall Survival as Monotherapy for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer Regardless of KR
Dec 9, 2019 06:46AM Merck (MRK) to Acquire ArQule (ARQL) for $20/Share in $2.7B Deal
Dec 9, 2019 06:45AM Merck to Acquire ArQule, Advancing Leadership in Oncology
Dec 5, 2019 06:49AM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA Approved in China as First-Line Maintenance Therapy in BRCAm Advanced Ovarian Cancer
Dec 5, 2019 06:45AM LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer
Dec 2, 2019 06:55AM Merck to Present at the Evercore ISI HealthCONx Conference 2019
Dec 2, 2019 06:46AM Merck (MRK) Announces FDA Grants Priority Review to its sBLA for KEYTRUDA in Certain Patients with High-Risk, NMIBC
Dec 2, 2019 06:45AM FDA Grants Priority Review to Merck’s Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Certain Patients with High-Risk, Non-Muscle Invasive Bladder Cancer (NMIBC)
Nov 26, 2019 08:00AM Japan and Singapore Grant CRISPR Patents to MilliporeSigma
Nov 26, 2019 06:48AM Merck's (MRK) KEYTRUDA Now Approved in China for First-Line Treatment of Metastatic Squamous NSCLC in Combination with Chemotherapy
Nov 26, 2019 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy
Nov 25, 2019 06:45AM New Survey of Young Adults Uncovers Low Levels of Accurate Knowledge About HIV Transmission Coupled with High-Risk Sexual Behaviors
Nov 20, 2019 06:48AM Merck (MRK) Reports EC Approval for Two New Regimens of KEYTRUDA (pembrolizumab) as 1st-Line Treatment for Metastatic or Unresectable Recurrent HNSCC
Nov 20, 2019 06:45AM European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
Nov 19, 2019 12:43PM Merck Announces First-Quarter 2020 Dividend
Nov 18, 2019 06:31AM Merck (MRK), Bayer’s Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure
Nov 18, 2019 06:30AM Merck and Bayer’s Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure
Nov 15, 2019 06:46AM Merck's (MRK) BRAVECTO PLUS for Cats Receives Approval from US FDA
Nov 15, 2019 06:45AM BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration
Nov 14, 2019 06:55AM US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review
Nov 12, 2019 08:00AM MilliporeSigma Licenses CRISPR Gene-Editing Technology to Evotec
Nov 11, 2019 03:02PM Merck's (MRK) ERVEBO Ebola Zaire Vaccine Granted Conditional Approval in European Union
Nov 11, 2019 03:00PM Merck’s ERVEBO® [Ebola Zaire Vaccine (rVSVΔG-ZEBOV-GP) live] Granted Conditional Approval in the European Union
Nov 8, 2019 08:00AM EMD Serono and Pfizer Provide Update on Phase III JAVELIN Gastric 100 Trial
View More Recent Stories View Older Stories